wire - news in brief
« BACK
Life Sciences - Pharmacology - 16.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - Health - 11.04.2019
Health - Pharmacology - 09.04.2019 
Animal-assisted therapy improves social behavior in patients with brain injuries
Animal-assisted therapy can foster social competence in patients with brain injuries and increase their emotional involvement during therapy. These were the findings of a clinical trial conducted by psychologists from the University of Basel and published in the journal Scientific Reports. After a severe traumatic brain injury, patients often exhibit problems in their social behavior.
Pharmacology - Business / Economics - 09.04.2019
Pharmacology - 04.04.2019
Health - Pharmacology - 04.04.2019 
New Project on Child Health in Tanzania
Fondation Botnar has awarded CHF 7 million to researchers from Lausanne for further deployment of electronic diagnostic and treatment tools based on algorithms, which will help clinicians to manage febrile children.
Health - Pharmacology - 03.04.2019
Pharmacology - Health - 03.04.2019
Pharmacology - Health - 02.04.2019
Pharmacology - Life Sciences - 01.04.2019
Pharmacology - Health - 01.04.2019
Pharmacology - Health - 01.04.2019
Pharmacology - Health - 27.03.2019
Pharmacology - Health - 19.03.2019
Pharmacology - Health - 15.03.2019
Health - Pharmacology - 14.03.2019
Pharmacology - 14.03.2019 
Drug use in Swiss cities unchanged
In a large-scale, Europe-wide drug monitoring project, the wastewater of around 38 million people in 85 cities was analysed in the spring.
Pharmacology - 14.03.2019
Pharmacology - Health - 14.03.2019
Pharmacology - Health - 11.03.2019
Health - Pharmacology - 11.03.2019
Pharmacology - Health - 11.03.2019
Pharmacology - Health - 08.03.2019
Health - Pharmacology - 07.03.2019
Pharmacology - Health - 07.03.2019
Pharmacology - Health - 05.03.2019
Pharmacology - Health - 28.02.2019
Pharmacology - Health - 25.02.2019
Health - Pharmacology - 25.02.2019
Pharmacology - Health - 19.02.2019
Pharmacology - Health - 19.02.2019
Pharmacology - Health - 13.02.2019
Pharmacology - Health - 06.02.2019
Pharmacology - Health - 05.02.2019
Pharmacology - Health - 01.02.2019
Pharmacology - Health - 01.02.2019
Pharmacology - Health - 30.01.2019
Pharmacology - Business / Economics - 30.01.2019
Pharmacology - Life Sciences - 22.01.2019
Pharmacology - Health - 17.01.2019
Pharmacology - Health - 08.01.2019
Pharmacology - Health - 07.01.2019
Pharmacology - Health - 21.12.2018
Health - Pharmacology - 21.12.2018
Pharmacology - Health - 20.12.2018
Pharmacology - Business / Economics - 20.12.2018
Health - Pharmacology - 19.12.2018
Health - Pharmacology - 17.12.2018
Pharmacology
Results 1 - 50 of 124.
AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1
Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human biodist
Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human biodist
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
Animal-assisted therapy can foster social competence in patients with brain injuries and increase their emotional involvement during therapy. These were the findings of a clinical trial conducted by psychologists from the University of Basel and published in the journal Scientific Reports. After a severe traumatic brain injury, patients often exhibit problems in their social behavior.
Fondation Botnar has awarded CHF 7 million to researchers from Lausanne for further deployment of electronic diagnostic and treatment tools based on algorithms, which will help clinicians to manage febrile children.
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.
Novartis first-in-class Cosentyx approved in China for psoriasis patients
China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first b
China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first b
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy AveXis plans
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy AveXis plans
Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alter
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alter
Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years Up to 80% of patients with relaps
Mayzent (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years Up to 80% of patients with relaps
FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
In a large-scale, Europe-wide drug monitoring project, the wastewater of around 38 million people in 85 cities was analysed in the spring.
European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara *
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
FDA grants Priority Review to Roche’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infes
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infes
Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application Ro
Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application Ro
CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Recommendation based on the Phase III IMpower150 study which showed that Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) helped people
Recommendation based on the Phase III IMpower150 study which showed that Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) helped people
CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people wit
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people wit
Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) - other company programmes in AD continue
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her
FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f
ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib)
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-li
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali (ribociclib), the CDK4/6 inhibitor with the largest body of first-li
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec
PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)
PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment
PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment